Scandion Oncology A/S (“Scandion Oncology”) today announces that the report on the in vivo animal data on antibiotic resistance SOM-001 is extended until mid-Q4 2019 due to shortage in slots at the provider. This will not affect the company’s goal of finding an overall strategy for commercializing SOM-001 in 2020.
Earlier this year Scandion Oncology announced that a number of its compounds are able to overcome antibiotic resistance in bacterial infections through a different mechanism of action than the one related to reversing resistance to anti-cancer drugs in cancer cells. As previously communicated, Scandion Oncology is to further evaluate the commercial strategy for the discovery. The company has chosen to conduct in vivo animal studies to further demonstrate the potential of the compounds. However, due to shortage in slots at the provider, the in vivo results are extended until mid-Q4 2019. This will not affect the company’s goal of finding an overall strategy for commercializing SOM-001 in 2020.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on October 1, 2019.
Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now ready to initiate clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.